These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 15989457)

  • 1. Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection.
    Mocroft A; Phillips AN; Soriano V; Rockstroh J; Blaxhult A; Katlama C; Boron-Kaczmarska A; Viksna L; Kirk O; Lundgren JD;
    AIDS Res Hum Retroviruses; 2005 Jun; 21(6):527-36. PubMed ID: 15989457
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection.
    Mocroft A; Phillips AN; Soriano V; Rockstroh J; Blaxhult A; Katlama C; Boron-Kaczmarska A; Viksna L; Kirk O; Lundgren JD;
    AIDS Res Hum Retroviruses; 2005 Sep; 21(9):743-52. PubMed ID: 16218797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Are specific antiretrovirals associated with an increased risk of discontinuation due to toxicities or patient/physician choice in patients with hepatitis C virus coinfection?
    Mocroft A; Rockstroh J; Soriano V; Ledergerber B; Kirk O; Vinogradova E; Reiss P; Katlama C; Phillips AN; Lundgren JD;
    Antivir Ther; 2005; 10(7):779-90. PubMed ID: 16312175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insights into reasons for discontinuation according to year of starting first regimen of highly active antiretroviral therapy in a cohort of antiretroviral-naïve patients.
    Cicconi P; Cozzi-Lepri A; Castagna A; Trecarichi EM; Antinori A; Gatti F; Cassola G; Sighinolfi L; Castelli P; d'Arminio Monforte A;
    HIV Med; 2010 Feb; 11(2):104-13. PubMed ID: 19732176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of hepatitis C coinfection on discontinuation and modification of initial HAART in primary HIV care.
    Hooshyar D; Napravnik S; Miller WC; Eron JJ
    AIDS; 2006 Feb; 20(4):575-83. PubMed ID: 16470122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of treatment complexity on adherence and incidence of blips in HIV/HCV coinfected patients.
    Calvo-Cidoncha E; González-Bueno J; Almeida-González CV; Morillo-Verdugo R
    J Manag Care Spec Pharm; 2015 Feb; 21(2):153-7. PubMed ID: 25615004
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre.
    Mocroft A; Youle M; Moore A; Sabin CA; Madge S; Lepri AC; Tyrer M; Chaloner C; Wilson D; Loveday C; Johnson MA; Phillips AN
    AIDS; 2001 Jan; 15(2):185-94. PubMed ID: 11216926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy.
    Rockstroh JK; Mocroft A; Soriano V; Tural C; Losso MH; Horban A; Kirk O; Phillips A; Ledergerber B; Lundgren J;
    J Infect Dis; 2005 Sep; 192(6):992-1002. PubMed ID: 16107951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased incidence of antiretroviral drug discontinuation among patients with viremic hepatitis C virus coinfection and high hyaluronic acid, a marker of liver fibrosis.
    Grint D; Peters L; Rockstroh JK; de Wit S; Mitsura VM; Knysz B; Pedersen C; Kirk O; Lundgren JD; Mocroft A;
    AIDS; 2014 Feb; 28(4):577-87. PubMed ID: 24468998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV and hepatitis C co-infection: the role of HAART in HIV/hepatitis C virus management.
    Jones M; Núñez M
    Curr Opin HIV AIDS; 2011 Nov; 6(6):546-52. PubMed ID: 22001896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of first antiretroviral treatment duration and outcome in HIV, HIV-HBV and HIV-HCV infection.
    Cooper CL; Mills E
    Int J STD AIDS; 2007 Aug; 18(8):546-50. PubMed ID: 17686217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of diabetes in HIV infected veterans pre- and post-HAART and the role of HCV coinfection.
    Butt AA; Fultz SL; Kwoh CK; Kelley D; Skanderson M; Justice AC
    Hepatology; 2004 Jul; 40(1):115-9. PubMed ID: 15239093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence of and risk factors for insulin resistance in treatment-naive HIV-infected patients 48 weeks after starting highly active antiretroviral therapy.
    Palacios R; Merchante N; Macias J; González M; Castillo J; Ruiz J; Márquez M; Gómez-Mateos J; Pineda JA; Santos J
    Antivir Ther; 2006; 11(4):529-35. PubMed ID: 16856627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of pill burden on discontinuation of the initial HAART regimen in minority female patients prescribed 1 pill/day versus any other pill burden.
    Hill S; Kavookjian J; Qian J; Chung A; Vandewaa J
    AIDS Care; 2014; 26(5):595-601. PubMed ID: 24111921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolution of HVR-1 quasispecies after 1-year treatment in HIV/HCV-coinfected patients according to the pattern of response to highly active antiretroviral therapy.
    Solmone M; Girardi E; Lalle E; Abbate I; D'Arminio Monforte A; Cozzi-Lepri A; Alessandrini A; Piscopo R; Ebo F; Cosco L; Antonucci G; Ippolito G; Capobianchi MR; ;
    Antivir Ther; 2006; 11(1):87-94. PubMed ID: 16518964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The associations between age and the development of laboratory abnormalities and treatment discontinuation for reasons other than virological failure in the first year of highly active antiretroviral therapy.
    Sabin CA; Smith CJ; Delpech V; Anderson J; Bansi L; Gilson R; Schwenk A; Leen C; Gazzard B; Porter K; Mackie N; Fisher M; Orkin C; Johnson M; Easterbrook P; Hill T; Phillips AN;
    HIV Med; 2009 Jan; 10(1):35-43. PubMed ID: 19018876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does hepatitis C viremia or genotype predict the risk of mortality in individuals co-infected with HIV?
    Rockstroh JK; Peters L; Grint D; Soriano V; Reiss P; Monforte Ad; Beniowski M; Losso MH; Kirk O; Kupfer B; Mocroft A;
    J Hepatol; 2013 Aug; 59(2):213-20. PubMed ID: 23583272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spontaneous clearance of hepatitis C virus in a patient co-infected with hepatitis C virus and human immunodeficiency virus: a case report.
    Kaung A; Sundaram V; Tran TT
    J Gastrointestin Liver Dis; 2014 Sep; 23(3):325-7. PubMed ID: 25267962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relationship between CD4 cell count nadirs and the toxicity profiles of antiretroviral regimens.
    Colette JS; Sabin CA; Lampe FC; Shah S; Tyrer M; Youle MS; Cropley I; Johnson MA; Phillips AN
    Antivir Ther; 2005; 10(3):459-67. PubMed ID: 15918337
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.